Showing results (171-180 of 456) with videos related to

Sort By:
Pageof 46
ESMO Open|June 17, 2022
Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancerB Tombal, C N Sternberg, M Hussain, et al.
The Lancet. Oncology|February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trialBertrand Tombal, Fred Saad, David Penson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 1, 1995
Prognostic impact of transurethral resection on patients irradiated for localized prostate cancerG Arcangeli, A Micheli, L Verna, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 14, 2006
High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG)V Pansadoro, P Emiliozzi, F depaula, et al.
The Journal of Allergy and Clinical Immunology|July 1, 1989
Are theophylline "levels" a reliable indicator of compliance?A F Kossoy, M Hill, F L Lin, et al.
American Journal of Clinical Oncology|June 10, 2011
Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinomaManuela Schmidinger, Cezary Szczylik, Cora N Sternberg, et al.
Oncology|October 16, 2015
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061Linda Cerbone, Cora N Sternberg, Lisa Sengeløv, et al.
Annals of Nuclear Medicine|November 29, 2015
A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-upMassimiliano Pacilio, Guido Ventroni, Bartolomeo Cassano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladderC N Sternberg, V Pansadoro, F Calabro, et al.
European Urology|October 24, 2008
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksHendrik Isbarn, Laurent Boccon-Gibod, Peter R Carroll, et al.
Pageof 46